

COVID-19 Vaccine Update

Caterina Liu, MD MPH
CDPH Immunization Branch

Janssen Updates

- Janssen COVID-19 vaccine is approved by the FDA under Emergency Use Authorization (EUA) in all persons aged ≥ 18 years
- Women < 50 years can receive any FDA-authorized COVID-19 vaccine, but should be aware of the rare risk of Thrombosis with Thrombocytopenia Syndrome (TTS) after the receipt of Janssen vaccine and the availability of other FDA-authorized vaccines.
- Pt with history of an episode of immune-mediated syndrome characterized by thrombosis and thrombocytopenia, such as HIT, should be offered mRNA vaccine if within 90-180 days of resolution of illness.
- People with a history of thrombosis or risk factors for thrombosis can receive any FDA-authorized vaccine, including the Janssen COVID-19 vaccine.
- People who take aspirin or blood thinners as part of their routine medications do not need to stop these medicines prior to the receipt of the Janssen COVID-19 vaccine.

[Safety Monitoring of the Janssen \(Johnson & Johnson\) COVID-19 Vaccine — United States, March–April 2021 | MMWR \(cdc.gov\)](#)

- 97% of reported side effects were classified as non-serious
- Most commonly reported side effects: HA, fever, chills, pain, fatigue
- 17 reports consistent with TTS (thrombosis with thrombocytopenia) out of almost 8 million doses administered
- More information on reported TTS cases:
 - [US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COVS Vaccination, March 2 to April 21, 2021 | Coagulation Disorders | JAMA | JAMA Network](#)

Updates: Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC

People vaccinated outside US:

- Complete series with World Health Organization (WHO)-approved COVID-19 vaccine – do not need to repeat vaccine series.
- Partially vaccinated or fully vaccinated with non-WHO approved vaccine – offer FDA-approved vaccine.
 - Wait at least 28 days from last dose of unauthorized vaccine.
- WHO-approved COVID-19 vaccines:
 - Pfizer-BioNTech
 - Moderna
 - Janssen
 - AstraZeneca

Updates: [Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC](#)

Contraindications and Precautions:

- Most people with a precaution can and should be administered COVID-19 vaccine.
- Polysorbate allergy is no longer a contraindication to mRNA vaccination.
- Known polysorbate allergy is a contraindication to Janssen COVID-19 vaccine and thus, a precaution to mRNA COVID-19 vaccination.
- Consultation available from the [Clinical Immunization Safety Assessment COVIDvax](#) project for providers of patients with complex clinical vaccine safety issues not readily addressed by CDC guidance.

CONTRAINDICATION TO VACCINATION	PRECAUTION TO VACCINATION
<p>History of the following:</p> <ul style="list-style-type: none"> • Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to component of the vaccine† • Immediate allergic reaction* of any severity after a previous dose or known (diagnosed) allergy to a component of the vaccine† 	<p>Among people without a contraindication, a history of:</p> <ul style="list-style-type: none"> • Any immediate allergic reaction* to other vaccines or injectable therapies‡ <p>Note: people with a contraindication to mRNA COVID-19 vaccines have a precaution to Janssen COVID-19 vaccine, and vice versa. See footnote for additional information on additional measures to take in these people.#</p>
<p>Actions:</p> <ul style="list-style-type: none"> • Do not vaccinate. • Consider referral to allergist-immunologist. • Consider other vaccine alternative.† 	<p>Actions:</p> <ul style="list-style-type: none"> • Risk assessment • Consider referral to allergist-immunologist • 30-minute observation period if vaccinated

[Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC](#)